Replies to post #42180 on $heff's $tation of $tocks & $olid DD

[$heff]

Watching OPXA ($1.73) more for a potential swing trade into the AAN. I do like that they received an SPA recently. The FDA thought enough of their data to believe that they warranted one as they start their Phase III study soon. I agree though that their data may not be as exciting as they lead investors to believe which is why I would not hold it for an extended period of time. Appreciate the DD links on prior PR's concerning their data. They were helpful!